Mao You-sheng, Zhang De-chao, Zhao Xiao-hang, Wang Liang-jun, Qi Jun, Li Xue-xiang
Department of Thoracic Surgical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):457-60.
To study the clinical significance of serum CEA, SCC and Cyfra21-1 test in the diagnosis, prediction of prognosis and postoperative monitor of recurrence in esophageal cancer.
The concentration of serum CEA and Cyfra21-1 was measured by electrochemiluminescence immunoassay (ECLIA) using Elecsys 2010, CEA kit and Cyfra21-1 kit. Serum SCC was measured by microparticle enzyme immunoassay (MEIA) using IMx System and SCC kit. Serum of 206 patients with esophageal cancer (203 squamous cell carcinoma, 2 small cell carcinoma and 1 adenosquamous carcinoma) was measured preoperatively, 71 of whom also measued 8 to 12 days after resection.
The cut-off value of CEA and Cyfra21-1 was < or = 3.25 ng/ml and < or = 2.61 ng/ml, which were determined by the data of 45 healthy Chinese measured during the same period. The positive ratios of serum CEA and Cyfra21-1 in 206 cases were 29.1% and 45.1%. The combined positive ratio of CEA and Cyfra21-1 was 57.3%. The CEA positive ratios, according to the pathological stage of 165 resectable patients, were 16.6% (stage I), 26.8% (II) and 30.8% (III). For Cyfra21-1, they were 27.8%, 37.5% and 50.5%. For CEA combined with Cyfra21-1, they were 38.9%, 50.0% and 63.7%. The mean value of CEA, SCC and Cyfra21-1 (especially SCC and Cyfra21-1) was found to be well correlated with the tumor volume, TNM stage and depth of tumor invasion. Patient with bulky tumor or advanced tumor (T4) usually had much higher mean value than those with early stage tumors. One week after radical resection, the level of the three tumor markers fell to normal level in 92.9% of 71 patients. The level of serum CEA and Cyfra21-1 varied greatly in a small part of the patients. Extremely elevated serum CEA and Cyfra21-1 usually indicated advanced lesion or tumor metastasis.
Preoperative and postoperative measurement of serum CEA, SCC and Cyfra21-1 (especially Cyfra21-1) is helpful in the diagnosis, prediction of prognosis and monitor of postoperative recurrence in patients with esophageal cancer.
探讨血清癌胚抗原（CEA）、鳞状细胞癌抗原（SCC）及细胞角蛋白19片段（Cyfra21-1）检测在食管癌诊断、预后预测及术后复发监测中的临床意义。
采用罗氏Elecsys 2010电化学发光免疫分析仪及配套的CEA、Cyfra21-1检测试剂盒，以电化学发光免疫分析法（ECLIA）测定血清CEA和Cyfra21-1浓度；采用雅培IMx系统及配套的SCC检测试剂盒，以微粒子酶免疫分析法（MEIA）测定血清SCC。对206例食管癌患者（203例鳞状细胞癌、2例小细胞癌和1例腺鳞癌）术前进行检测，其中71例患者术后8～12天也进行了检测。
同期检测45例健康中国人血清，确定CEA和Cyfra21-1的临界值分别为≤3.25 ng/ml和≤2.61 ng/ml。206例患者血清CEA和Cyfra21-1的阳性率分别为29.1%和45.1%，两者联合检测的阳性率为57.3%。165例可切除食管癌患者中，根据病理分期，CEA的阳性率分别为：Ⅰ期16.6%、Ⅱ期26.8%、Ⅲ期30.8%；Cyfra21-1的阳性率分别为27.8%、37.5%、50.5%；CEA联合Cyfra21-1的阳性率分别为3
